Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Condition:   Multiple Myeloma Intervention:   Biological: IM21 CAR-T cells Sponsor:   Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials